Queensland has fortunately stricken a big deal with the biotech giant Merck, which has enabled it to easily start up Vaxxas and relocate it to Massachusetts.

Merck, the known biotech giant, is one of the largest vaccine firms in the world and so has the onset of the research collaboration deal between Vaxxas and Merck, is being expected to soon produce some big results with their plans to evaluate a Nanopatch product that will provide needle-free vaccinations.

According to the recent agreement between both the firms, Merck will be providing the funding to Vaxxas, helping it in the development and commercialization of Nanopatch, in return to which, Merck will enjoy an exclusive license of developing the Nanopatch for its own vaccination product.

The deal will also see Vaxxas, a spin-off of the University of Queensland, moving to Cambridge in Massachusetts whereas few research and development will still continue at the university only.

Anticipations are being made that the relocation of vaxxas to the US will help it in striking some more partnership deals with other investors too enabling it to expand its presence across the huge American market.

"We are pleased to collaborate with Merck, a recognized global leader in vaccines, to apply our technology with their expertise in vaccines research," says Vaxxas CEO Mr. David Hoey.